A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in participants with head and neck squamous cell carcinoma (HNSCC).
Key Inclusion Criteria:
Safety Run-in Cohort 1 and Phase 2 Cohorts 1
Safety Run-in Cohort 2 and Phase 2 Cohort 3
Key Exclusion Criteria:
Safety Run-in Cohort 1, Pre-expansion Safety Run-in Cohort for Magrolimab + Pembrolizumab (if Applicable), and Phase 2 Cohorts 1 and 2
Prior treatment with any of the following:
Safety Run-in Cohort 2 and Phase 2 Cohort 3
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Redondo Beach, California 90277, United States
New York, New York 10029, United States
Libramont-Chevigny, 6800, Belgium
Nice, 6189, France
GÃttingen, 37075, Germany
Gliwice, 44-102, Poland
Poznan, 61-866, Poland
Warsaw, 2781, Poland
Matosinhos Municipality, 4464-513, Portugal